Business
TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":" BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective June 1, 2020. Mr. Cartwright will remain with the Company as an advisor for a transitional period. Mr. D’Arecca joins TherapeuticsMD with broad experience in corporate and operational finance, most recently as Senior Vice President and Chief Accounting Officer of Allergan plc.\n\n\n“I can’t imagine a more exciting time to join TherapeuticsMD,” says Mr. D’Arecca. “Having spent time in the women’s health market while at Allergan, I believe that TherapeuticsMD is well positioned to redefine women’s healthcare with a full portfolio of new and innovative products. I look forward to working with all my new colleagues as we position the company and our portfolio for continued growth.”\n\n\n“I am thrilled that James has agreed to join TherapeuticsMD,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “James is a seasoned executive with a wealth of experience supporting high-growth commercially-focused pharmaceutical businesses and has a history of providing strong financial discipline and leadership. We look forward to adding James to our executive team. I believe he will help us continue our drive to build long-term shareholder value.\"\n\n\n“I also want to congratulate Dan on his retirement,” said Mr. Finizio. “We want to thank him for nine years of outstanding service and dedication to our Company.”\n\n\nAbout James C. D’Arecca\n\n\nPrior to joining TherapeuticsMD, Mr. D’Arecca served as the Senior Vice President and Chief Accounting Officer of Allergan plc (formerly known as Actavis plc) from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the finance team through Allergan’s journey from a generics manufacturer (Watson/Actavis) to a leading global pharmaceutical company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where he served as its Chief Accounting Officer. Prior to Bausch & Lomb, he served in various roles of increasing responsibility at Merck & Co. Inc. and Schering-Plough in finance and business d...